Please assess the completion status of the following clinical trial:

Trial Title: Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from parent(s) or legal guardian(s).~* Age:~Cohort I: 12 - 23 mo. Cohort II: 9 - 11 mo. Cohort III: 6 - 8 mo. Cohort IV: 3 - 5 mo. Cohort V: 0 - 2 mo.~* Confirmed laboratory diagnosis of influenza by viral culture or rapid influenza diagnostic test within 96 hours prior to study enrollment.~* Duration of influenza symptoms less than or equal to 96 hours.~Exclusion Criteria:~* Concomitant vomiting illness that would preclude ability to take drug.~* Immunocompromised subject (e.g., malignancy, congenital agammaglobulinemia, HIV).~* Documented renal impairment (e.g., polycystic renal disease, nephrectomy, renal transplantation, renal agenesis, dialysis requirement, renal failure, nephrotic syndrome at any time prior to enrollment, current receipt of diuretic therapy).~* Documented hepatic impairment (e.g., congenital hepatitis, biliary atresia, cholelithiasis).~* Gastrointestinal abnormality which might hinder absorption of an oral medication.~* Current receipt of inotropic drugs (e.g., epinephrine, norepinephrine, dopamine, dobutamine).~* History of seizures.~* Documented congenital malformations of the central nervous system defined at birth (e.g., hydranencephaly, prosencephaly, spina bifida).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- oseltamivir (Tamiflu®) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).